Noninvasive Therapy Shows Efficacy in Non-Muscle-Invasive Bladder Cancer
WASHINGTON — An investigational non-surgical treatment led to a “robust” complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study showed. Patients treated with the UGN-102 (mitomycin) intravesical solution achieved a complete response rate of 79.2% (95% CI 73.5-84.1) at 3 months without having to undergo transurethral resection of […]